Logo image of PASG

PASSAGE BIO INC (PASG) Stock Fundamental Analysis

NASDAQ:PASG - Nasdaq - US7027121000 - Common Stock - Currency: USD

0.33  +0 (+0.3%)

After market: 0.33 0 (0%)

Fundamental Rating

2

Overall PASG gets a fundamental rating of 2 out of 10. We evaluated PASG against 568 industry peers in the Biotechnology industry. PASG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PASG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PASG has reported negative net income.
PASG had a negative operating cash flow in the past year.
In the past 5 years PASG always reported negative net income.
In the past 5 years PASG always reported negative operating cash flow.
PASG Yearly Net Income VS EBIT VS OCF VS FCFPASG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

PASG has a worse Return On Assets (-63.24%) than 61.62% of its industry peers.
PASG has a Return On Equity of -105.72%. This is comparable to the rest of the industry: PASG outperforms 44.37% of its industry peers.
Industry RankSector Rank
ROA -63.24%
ROE -105.72%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-54.67%
ROE(3y)-88.34%
ROE(5y)-72.01%
ROIC(3y)N/A
ROIC(5y)N/A
PASG Yearly ROA, ROE, ROICPASG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

PASG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PASG Yearly Profit, Operating, Gross MarginsPASG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PASG has more shares outstanding
Compared to 5 years ago, PASG has more shares outstanding
There is no outstanding debt for PASG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PASG Yearly Shares OutstandingPASG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PASG Yearly Total Debt VS Total AssetsPASG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PASG has an Altman-Z score of -10.12. This is a bad value and indicates that PASG is not financially healthy and even has some risk of bankruptcy.
PASG has a worse Altman-Z score (-10.12) than 74.12% of its industry peers.
PASG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.12
ROIC/WACCN/A
WACCN/A
PASG Yearly LT Debt VS Equity VS FCFPASG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.07 indicates that PASG has no problem at all paying its short term obligations.
The Current ratio of PASG (4.07) is comparable to the rest of the industry.
PASG has a Quick Ratio of 4.07. This indicates that PASG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.07, PASG is in line with its industry, outperforming 49.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07
PASG Yearly Current Assets VS Current LiabilitesPASG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

PASG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.47%, which is quite impressive.
EPS 1Y (TTM)42.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PASG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.46% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.83%
EPS Next 2Y12.23%
EPS Next 3Y23.33%
EPS Next 5Y29.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PASG Yearly Revenue VS EstimatesPASG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
PASG Yearly EPS VS EstimatesPASG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PASG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PASG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PASG Price Earnings VS Forward Price EarningsPASG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PASG Per share dataPASG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as PASG's earnings are expected to grow with 23.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.23%
EPS Next 3Y23.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PASG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PASSAGE BIO INC

NASDAQ:PASG (4/17/2025, 8:00:02 PM)

After market: 0.33 0 (0%)

0.33

+0 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2025-03-04/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners49.62%
Inst Owner Change0%
Ins Owners0.16%
Ins Owner Change0.04%
Market Cap20.51M
Analysts85.45
Price Target6.89 (1987.88%)
Short Float %3.32%
Short Ratio5.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.13%
Min EPS beat(2)-32.14%
Max EPS beat(2)3.88%
EPS beat(4)3
Avg EPS beat(4)1.81%
Min EPS beat(4)-32.14%
Max EPS beat(4)17.77%
EPS beat(8)5
Avg EPS beat(8)1.73%
EPS beat(12)9
Avg EPS beat(12)7.28%
EPS beat(16)10
Avg EPS beat(16)4.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.57%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.5%
EPS NY rev (1m)-24.62%
EPS NY rev (3m)-24.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.24%
ROE -105.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-54.67%
ROE(3y)-88.34%
ROE(5y)-72.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z -10.12
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)49.41%
Cap/Depr(5y)403.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y21.83%
EPS Next 2Y12.23%
EPS Next 3Y23.33%
EPS Next 5Y29.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.53%
EBIT Next 3Y6.96%
EBIT Next 5Y23.29%
FCF growth 1Y38.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.73%
OCF growth 3YN/A
OCF growth 5YN/A